Genuine Biotech takes third shot at IPO as financial pressures mount
Demand for the company’s core product has long since faded, and sales for the product took an additional hit after the termination of a distribution partnership with Fosun Pharma Key…
FAST NEWS: WuXi AppTec Sees Profit Doubling in First Three Quarters
The latest: Pharmaceutical services outsourcing company WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) on Thursday estimated its revenue in the first three quarters of this year rose 71.87% to 28.4 billion…
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK - If you don’t succeed at first, second or third? FWD takes a fourth try at Hong Kong IPO
-
So big but so what? Innovent’s license deal fails to excite investors
1801.HK
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
InnoCare licensing deal flops due to lack of upfront cash
9969.HK 688428.SHG
- Intsig scans global financial markets for cash with Hong Kong IPO
